Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 25 | 2022J&J Q4 '21 Earnings Update; Glytec Partners with Nebraska Medicine; Daewoong Pharma Announces Positive Ph3 Enavogliflozin Results in T2DMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, Other, SGLT2i Jan 24 | 2022Jardiance HFpEF Indication Extension Up for Adoption; January 24-27 CHMP AgendaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Jan 21 | 2022FDA Approves Lannett’s Bs-glargine IND; Biocon CY Q4 '21 (FY Q3 '22) Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Jan 20 | 2022Arecor Initiates Ph1 Ultra-Rapid Insulin Trial in T1DMPurchase Blast
$599
Posted in: Basal Insulin, Other Jan 19 | 2022Viatris Recalls One Batch of Non-interchangeable Semglee Prefilled Pens; Dario Hosts 2022 Investor WebinarPurchase Blast
$599
Posted in: Other Jan 18 | 2022Lilly Partners with Abbisko Therapeutics and Evotec; Novo Partners with EraCal Therapeutic; Fractyl Announces Initial Interim Feasibility DataPurchase Blast
$599
Posted in: Other Jan 14 | 2022Can Michael Davidson Strike Gold Again with NewAmsterdam’s CETPi?Purchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Jan 13 | 2022JPM 2022 Day 4: Lexicon and Esperion; Imcyse Reports Positive Data from Interim Analysis of Ph2 IMPACT Trial; vTv Therapeutics Provides Update on TTP399 Development; Nemaura Launches Miboko to Employers and InsurersPurchase Blast$599
Posted in: Bolus Insulin, Other Jan 12 | 2022JPM 2022 Day 3: Akebia, Ionis, and Hikma; Oramed Provides Updates on Ph3 Oral Insulin ProgramPurchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring, Other Jan 11 | 2022JPM 2022 Day 2: LLY, ABT, AMRN, SNY, AMGN, RHHBY, and TEVAPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Jan 10 | 2022JPM 2022 Day 1: DXCM, NVS, BAYRY, MDT, TDOC, VRTX; Sanofi Partners with BrightInsight; Viking Initiates GLP-1/GIP Dual Agonist Ph1 TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Other Jan 07 | 2022Senseonics Announces FDA Review for 180-day CGM Nearing Completion; Alnylam and Novartis Announce Collaboration for Liver FailurePurchase Blast
$599
Posted in: Glucose Monitoring, Other Jan 06 | 2022Abbott Announces New Category of Biowearables at CES 2022Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 03 | 2022Holiday Hangover: Novo Completes Dicerna Acquisition; FDA Approves Novartis’s Leqvio; Lexicon Submits NDA for Sotagliflozin; CMS Medicare Coverage Expansion Includes Non-adjunctive CGMs; Viatris Beats Sanofi’s Insulin-Pen Patent Invalidation Appeal; Beta Bionics iLet Bionic Pancreas Pivotal Trials UpdatePurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA Dec 20 | 2021Novo Hosts Wegovy Shortage Call with Investors; Lannett Files Bs-glargine IND; Provention Adds New Management; Intercept NASH Data DelayedPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Dec 17 | 2021Novo Faces New Wegovy Supply ShortagePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Dec 16 | 2021Medtronic Diabetes Receives FDA Warning; Bigfoot Hires New Senior Leaders; Omada’s mHealth Programs Gain Preferred Status on Evernorth Digital Health FormularyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Dec 15 | 2021Lilly Hosts 2021 Investment Community MeetingPurchase Blast
$599
Posted in: Other Dec 14 | 2021Sigilon Announces Strategic Reprioritization; Jaguar Gene Therapy Includes T1DM in Initial Pipeline ProgramPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, Other, SGLT2i Dec 13 | 2021December 13-16 CHMP Agenda; Novo Invests Further in Kalundborg Manufacturing Facilities; CytoDyn Reports Additional Data from Ph2 Leronlimab NASH Trial; Adocia Files Patent for Oral Delivery Technology of PeptidesPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
